Haven Capital Group Inc. Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Haven Capital Group Inc. purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 13,704 shares of the company’s stock, valued at approximately $5,666,000. IDEXX Laboratories accounts for 5.3% of Haven Capital Group Inc.’s investment portfolio, making the stock its 5th largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. William Blair Investment Management LLC raised its position in IDEXX Laboratories by 701.6% during the 4th quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after buying an additional 369,471 shares during the last quarter. Cibc World Markets Corp increased its stake in shares of IDEXX Laboratories by 13.1% during the fourth quarter. Cibc World Markets Corp now owns 14,744 shares of the company’s stock worth $6,096,000 after acquiring an additional 1,709 shares during the period. Jensen Investment Management Inc. raised its holdings in IDEXX Laboratories by 11.5% during the fourth quarter. Jensen Investment Management Inc. now owns 9,020 shares of the company’s stock worth $3,729,000 after purchasing an additional 930 shares in the last quarter. Glenview Trust co lifted its position in IDEXX Laboratories by 152.8% in the fourth quarter. Glenview Trust co now owns 16,812 shares of the company’s stock valued at $6,951,000 after purchasing an additional 10,162 shares during the period. Finally, Centurion Wealth Management LLC boosted its holdings in IDEXX Laboratories by 16.4% in the 4th quarter. Centurion Wealth Management LLC now owns 846 shares of the company’s stock valued at $350,000 after purchasing an additional 119 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $422.36 on Tuesday. The company has a 50-day moving average of $437.89 and a two-hundred day moving average of $446.30. The stock has a market cap of $34.35 billion, a P/E ratio of 39.58, a PEG ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective for the company. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.